Chengdu Olymvax Biopharmaceuticals (688319) Stock Overview
Engages in the research and development, production, and sales of vaccines for human use. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
688319 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Chengdu Olymvax Biopharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.08 |
| 52 Week High | CN¥18.74 |
| 52 Week Low | CN¥8.10 |
| Beta | 0.66 |
| 1 Month Change | 7.20% |
| 3 Month Change | 12.76% |
| 1 Year Change | 66.46% |
| 3 Year Change | -17.07% |
| 5 Year Change | n/a |
| Change since IPO | -59.70% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) With Shares Advancing 35%
Mar 06
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Using Too Much Debt?
Feb 12Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected
Oct 09We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26Shareholder Returns
| 688319 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -7.0% | -3.6% | -0.2% |
| 1Y | 66.5% | 6.0% | 13.6% |
Return vs Industry: 688319 exceeded the CN Biotechs industry which returned 6% over the past year.
Return vs Market: 688319 exceeded the CN Market which returned 13.6% over the past year.
Price Volatility
| 688319 volatility | |
|---|---|
| 688319 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688319's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688319's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 470 | Shaowen Fan | www.olymvax.com |
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use. It offers adsorbed tetanus vaccine; Hib conjugate vaccine; Group A streptococcus vaccine; and AC conjugate vaccine. The company also provides vaccines for haemophilus influenzae type b; group A and C meningococcal; and staphylococcus aureus, which is in Phase 3 clinical trial.
Chengdu Olymvax Biopharmaceuticals Inc. Fundamentals Summary
| 688319 fundamental statistics | |
|---|---|
| Market cap | CN¥6.56b |
| Earnings (TTM) | CN¥39.68m |
| Revenue (TTM) | CN¥605.55m |
Is 688319 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688319 income statement (TTM) | |
|---|---|
| Revenue | CN¥605.55m |
| Cost of Revenue | CN¥30.16m |
| Gross Profit | CN¥575.39m |
| Other Expenses | CN¥535.71m |
| Earnings | CN¥39.68m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.098 |
| Gross Margin | 95.02% |
| Net Profit Margin | 6.55% |
| Debt/Equity Ratio | 40.8% |
How did 688319 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/18 12:36 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chengdu Olymvax Biopharmaceuticals Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiabo Zhang | Guosen Securities Co., Ltd. |
| Yinglan Shu | Haitong International Research Limited |
| Jiaxi Xu | Industrial Securities Co. Ltd. |